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The high degree of tissue tropism of many infectious agents can, in part, be 
explained by their recognition of specific epithelial cell receptor sites. Binding 
to  these  receptors  results  in  attachment  (1-3).  Streptococcus pneumoniae  is  a 
constituent of the flora in the healthy nasopharynx as well as a cause of localized 
or  invasive  infection  (4-6).  Pneumococcal  isolates  from  the  nasopharynx  of 
patients  with  otitis  media  or  healthy carriers  adhered  more avidly to  human 
nasopharyngeal  epithelial  cells  than  isolates  from patients  with  septicemia  or 
meningitis (7).  Adhesive capacity  may thus  localize  pneumococci to that  site. 
Consequently,  classification  of  mechanisms  of  binding  may  provide  tools  to 
interfere with the bacterial colonization. 
Pneumococci associate with numerous macromolecules (8-10). C-reactive pro- 
tein binds the C-polysaccharide through the phosphorylcholine moiety (11). The 
collagen-binding region of human serum fibronectin can bind to as yet undefined 
pneumococcal surface structures. 1 The binding of pneumococci to cells varies 
with species,  individual, and tissue in a  manner suggesting specific binding of 
bacterial  adhesins and epithelial cell receptors (reference  7, and Andersson et 
al.,  unpublished  observations).  A  proteinaceous  pneumococcal  adhesion  was 
suggested since attachment was abolished by heating or protease  treatment of 
the bacteria (7).  Interactions of protein adhesins with epithelial cell receptors of 
a glycolipid nature were previously shown to explain the attachment of uropath- 
ogenic Escherichia coli to human uroepitheliai cells (2,  12).  More specifically, a 
Galal---~4Gal3-moiety  was  shown  to be  the  minimal component sufficient (al- 
though  not optimal)  for  binding (12,  13).  This  paper  presents  evidence that 
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to the collagen-binding  region of fibronectin on human pharyngeal epithelial  cells (manuscript in 
preparation). 
J. ExP. MED. © The Rockefeller University Press • 0022-1007/83/07/559/12 $1.00  559 
Volume 158  August 1983  559-570 560  A  RECEPTOR  FOR  PNEUMOCOCCI ADHERING  TO PHARYNGEAL CELLS 
attaching pneumococci specifically bind glycoconjugate receptors containing the 
disaccharide GIcN  Ac/31---*3Gal/3-. 
Materials and Methods 
Bacteria.  The two strains of S. Pneumoniae,  EF3114 and EF10276 (both of capsular 
type 6A, isolated from the nasopharynx of  patients with otitis media) were used throughout 
the study. To test the generality of the proposed receptor structure the following strains 
were included: EF2987 (capsular type 23F), EF3030 (type 19F), EF3296 (type 4), EF3559 
(type 14),  isolated from patients with otitis, EF7509 (type 25) and EF1488 (type 15A) 
from patients with meningitis, and EF 10175 (type 19F) isolated from the nasopharynx of 
a healthy carrier. The strains were kept lyophilized. For adherence testing the lyophils 
were transferred to blood agar plates and cultured over night, then grown for 18 h in 50 
ml of the synthetic medium of van der Rijn and Kessler (14) supplemented with 2 g/l of 
ascorbic acid and as described in (15). Bacteria were harvested by centrifugation at 3,000 
g for 20 rain, and suspended in 1 ml of saline (7). 
Glycoconjugates.  The structures of the glycoconjugates and oligosaccharides used are 
listed in Table I. Human plasma fibronectin was isolated according to (22,  23).  E.  coli 
lipopolysaccharides (LPS)  from smooth strains of serotypes 04 and 083 and from rough 
mutants  with  core structures R1,  R2,  Rs,  and  R4  were prepared by hot phenol water 
extraction (24). 
The glycolipids neolactotetraosylceramide, N-acetylneuraminosylneolactotetraosylcer- 
amide, and globotetraosylceramide were isolated from human erythrocytes. The glyco- 
lipids were prepared by chloroform-methanol extraction, mild alkaline hydrolysis, dialysis, 
diethylaminoethyl-cellulose chromatography and silicic acid chromatography (25).  The 
neutral glycolipids were further purified as their acetylated derivatives (26) and were at 
least 95% pure judged by thin layer chromatography. For the preparation of neolacto- 
tetraosylceramide, N-acetylneuraminosylneolactotetraosylceramide  (the major ganglioside 
of human erythrocytes [27]) was isolated and degraded by Vibrio cholerae neuraminidase 
(Calbiochem-Behring Corp., San Diego, CA).  The glycolipid structures were confirmed 
by mass spectrometry, nuclear magnetic resonance (NMR) spectroscopy and degradative 
methods  (28-30  also  references in  31).  For testing,  the  glycolipids were  taken  from 
chloroform methanol solutions, cleared of solvent in a stream of nitrogen, desiccated over 
night, and suspended in NaCI by sonication in a water bath. 
The tetrasaccharides neolactotetraose and lactotetraose were isolated from human milk 
(20). The octasaccharide was isolated from the urine of a patient with GMl-gangliosidosis 
(21).  The structures were confirmed by mass spectrometry and inferred by paper chro- 
matography. 
The following compounds (C.f. Table I) were prepared by synthesis (to be reported 
elsewhere). The structures were confirmed by NMR and physical methods. Briefly: 
Ethyl 4-O-~-D-galactopyranosyl-~-o-glucopyranoside (9): [a]~  l -  1.7 ° (c 1.0, water); NMR data: 
~H (DMSO-d6,  50°C, plus 020) ~$ 4.28-4.16 (3H, inter alia  H-1 and H-1 '), 1.14 (t, 3H, J 
7 Hz, CH3).  ~sC (D20, TSP) 6 105.8,  104.6 (2d, J  158 and 155  Hz, C-1 and C-I'),  17.1 
(CH~). 
Methyl 2-aceta  mido-2-deoxy-4-O-(~-D-galactopyranosyl)-~x-D-glucopyranoside (10): [ot]~  l + 8,  0.4 ° (c 
0.5, water); NMR data: ~H (D20) 6 4.78 (d,J 3.4 Hz, H-l), 4.48 (d,J 7.1 Hz, H-1  ), 3.39 
(s, OMe), 2.03 (s, COMe); ~sC (D~O) fi 105.8 (C-I'), 100.6 (C-l), 58.1 (OMe), 56.1 (C-2), 
24.7 (COCHs). 
Methyl 2-acetamido-2-deoxy-4-O-(13-o-galactopyranosyl)-~-o-glucopyranoside (11): m.p. decompo- 
sition, [a]2~ _  16  (c 1, water); Lit. (32): m.p. decomp., [a]g  3-  16.7  (c 0.3, water). 
Ethyl 2-aceta  mido-2-deoxy-4-O-(O-o-galactopyranosyl)-[J-o-glucopyranoside (12): was reported ear- 
lier (33). 
2 Abbreviations used in this paper." EID75, effective inhibitory dose reducing adherence to 25% of the 
saline control (75% inhibition); LPS, lipopolysaccharide;  m.p., melting point; NMR, nuclear magnetic 
resonance spectroscopy. T
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2-Acetamido-2-deoxy-4-O-([3-o-galactopyranosyl)-o-glucose  (13): Physical data were determined 
for the  a-per-O-acetate: m.p.  224-225  C,  [a]~  I +  58.6 °  (c 0.9,  chloroform);  Lit.  (34): 
m.p. 224-225°C, [a]g  ° +  58 ° (c 1, chloroform). 
Methyl 4-O-(2-acetamido-2-deoxy-[J-D-glucopyranosyl)-13-o-galactopyranoside  (14): [a]g  5 -  19 ° (c 
0.3, water); NMR data:  IH (D20) 6 4.70 (d,J 8.3 Hz, H-I'), 4.30 (d,J 7.9 Hz, H-l), 3.53 
(s, OMe), 2.04 (s, COMe); 13C (D20) fi 106.5,  104.9 25.1  (COCH~). 
Methyl 3-O-(2-acetamido-2-deoxy-~3-o-glucopyranosyt)-~-o-galactopyranoside  (15): [a]g  1 +  3.6 ° (c 
0.4, water); NMR data: ~H (D20) 6 4.69 (d,J 8.5 Hz, H-1 '), 4.30 (d,J 7.8 Hz, H-l), 3.56 
(s, OMe), 2.03  (s, COMe);  ~3C (D20) ~ 106.7 (C-I),  105.5  (C-I') 60.0 (OCH3), 58.5  (C- 
2'), 25.0 (COCH~). 
Bacterial Binding Assays 
Epithelial Cell Adherence.  The binding  to human  nasopharyngeal epithelial cells was 
assayed in  vitro as previously described (7).  Saline suspension of bacteria (109/ml) and 
pharyngeal epithelial cells from a  healthy male donor (104/ml) were mixed to an end 
volume of 200 #1, centrifuged at 1,500 g for 10 min, and incubated at 37°C for 30 min. 
After washing twice in 2.5 ml of saline to separate epithelial cells from unattached bacteria 
the number of bacteria adhering to 40 epithelial cells were counted and the mean number 
per cell was determined. 
Hemagglutination.  Adhering  bacteria may be expected to bind to any target cell or 
surface  where  receptors  are  present.  Bacterial  binding  to  erythrocytes,  resulting  in 
hemagglutination has been a  useful tool to approach mechanisms of binding.  Thus, the 
ability of the adhering pneumococci to agglutinate erythrocytes was investigated. Freshly 
drawn citrated blood was washed and 5% suspensions in saline of human, bovine, rabbit, 
and guinea pig erythrocytes were prepared. Human O, A, B, AB, and cord blood samples 
were provided by the blood bank of Sahlgren's Hospital, G6teborg, Sweden. For enzymatic 
treatment the 5% suspensions were mixed with Papain (Kebo Grave, Stockholm, Sweden) 
or neuraminidase (Sigma Chemical Co., St. Louis, MO) to a final concentration of 1 mg/ 
ml and rotated at 37°C for 30 min. After washing twice the suspension was readjusted to 
5%.  Bacterial and erythrocyte suspensions (25 t*l of each) were mixed on a  microscope 
slide, and agglutination read by the naked eye. 
Screening for Receptor Activity of the Glycoconjugates 
Receptor activity of glycoconjugates or free oligosaccharides, was assayed in two main 
ways. 
(a)  Inhibition  of binding  by excess  of the  free  sugar.  The  bacterial  inoculum  was 
preincubated with dilutions of the compounds with potential receptor activity, for 15 rain 
at  37°C.  Subsequently  epithelial  cells  were  added  and  adhesion  testing  proceeded  as 
described. The adhesion of the treated samples is given in per cent of the saline control. 
The variation between experiments is described by the range.  The effective inhibitory 
oligosaccharide dose, EID75, required for 75% inhibition of adhesion is given. 
(b)  Induction  of binding  by  coating  with  receptor.  Association  of receptor-active 
glycolipids with  epithelial cells or erythrocytes might increase the  bacterial binding  to 
epithelial cells already containing the receptor or induce binding to cells previously lacking 
the  receptor (12).  Rabbit erythrocytes (100  #1  of a  5%  suspension)  were  mixed  with 
neolactotetraosylceramide,  sialylneolactotetraosylceramide,  or  globotetraosylceramide 
(500 #1 of suspensions of 200 tag/ml) and incubated at 37 ° for 3 h during rotation (12). 
After elimination of unbound glycolipid by repeated washing, the erythrocyte concentra- 
tion was readjusted to 5% and used for hemagglutination. In parallel with the adherence 
inhibition assays the human nasopharyngeal epithelial cells were pretreated with decreas- 
ing  concentrations  of glycolipid,  incubated  for  2  h  at  37°C,  washed,  and  used  for 
adherence testing. 
Results 
Initial  Studies.  The  focus  on  the  neolactoseries  of  glycolipids  as  receptor 
candidates resulted from work with other glycoconjugates. Human plasma fibro- ANDERSSON  ET  AL.  563 
nectin  inhibited  adhesion  (42%  of  saline  control  at  100  #g/ml).  Increased 
attachment was obtained after pretreatment  of the epithelial cells with  1 mg/ml 
of fibronectin (Table II). E. coli LPS of serotypes 04 and 083 completely inhibited 
adhesion at  1 mg/ml.  Partial inhibition resulted after pretreatment  with R3 LPS 
at  1 mg/ml;  R~,  R2, and  R4 were not inhibitory.  No decrease  in pneumococcal 
viability after  treatment  with  glycoconjugates was detected  by viable counts  on 
10-fold saline dilutions. 
Compounds  with potential  receptor activity were selected  for testing  because 
of structural  similarity  to  the  known  oligosaccharide  sequences  of fibronectin 
and Ra LPS. 
Glycolipids.  The  receptor  activity  of  the  glycolipids  is  shown  in  Table  II. 
Pretreatment of the pneumococci with neolactotetraosylceramide inhibited adhe- 
TABLE  II 
Effect of Glycoconjugates on the Adhesion of Pneumococci to Human Pharyngeal Epithelial Cells 
Adhesion*  Adhesion* 
Compound  Concen-  Concen- 
tration  % of saline control  No.  tration  % of saline control  No. 
Mean  Range  exp.  Mean  Range  exp. 
#g/ml  ~g/ml 
Fibronectin ~  100  42  23-50  3  1,000  234  --  1 
Neolactotetraosyl-  200  59  22-100  6  200  190  85-244  4 
ceramide 
Sialylneolacto-  200  100  93-108  3  200  94  65-127  3 
tetraosylceramide 
Globotetraosyl-  --  200  100  --  1 
ceramide 
* Bacteria were preincubated with the glycoconjugates before addition of epithelial cells (competitive 
inhibition). 
* Epithelial  cells were preincubated with  glycoconjugate,  washed  and used  for adherence testing 
(coating). 
0 More data in reference 12. 
TABLE  III 
Inhibition of Pneumococcal Adhesion by Natural Oligosaccharides 
Adhesion 
No. in Ta-  Concen- 
Oligosaccharide  ble I  tration  % of saline control  No. exp. 
Mean  Range  EID75* 
mg/ml  mg/ml 
Neolactotetraose  5  10  1  0-2  3 
5  0  0-0  4 
1  28  14-56  1.5  5 
0.1  52  36-63  4 
Lactotetraose  6  5  4  2-5  3 
1  25  14-45  1.0  3 
0.1  68  55-81  2 
~Octasaccharide"  7  5  71  43-116  3 
1  62  53-78  >10  3 
0.1  141  47-235  2 
* EID75 = effective inhibitory dose reducing adherence to 25% of the saline control (75% inhibition). 564  A  RECEPTOR  FOR  PNEUMOCOCCI  ADHERING  TO PHARYNGEAL  CELLS 
TABLE  IV 
Inhibition of Pneumococcal Adhesion by Synthetic Disaccharides 
Adhesion 
No. in Table 
Disaccharide  I  Concentration  % of saline control  No. exp. 
Mean  Range  EID75 
GalB 1--~4Glc  8 
Gal/31--~Glc~ 1-O-Et  9 
Gal/31---~4GIcNAca 1-O-  10 
Me 
Gal/31---~GlcN Acl31  -O-  II 
Me 
GalOl--~GIcNAcOl-O-  12 
Et 
Gall31---,4GIcNAc  13 
GIc Nac/31---*4Gal/3-O-  14 
Me 
GlcNAcE  1---*3Gal~-O-  15 
Me 
mg/ml  mg/ml 
10  101  100-102  >10  2 
5  107  100-111  2 
1  97  76-118  2 
10  63  48-77  >10  2 
5  78  69-86  2 
1  85  83-86  2 
10  129  111-146  >10  2 
5  98  71-127  2 
1  96  --  1 
10  29  26-35  >10  3 
5  45  32-53  4 
1  96  88-103  2 
10  31  28-34  >10  2 
5  38  21-54  2 
1  67  59-74  2 
10  127  12-251  >10  4 
5  144  58-335  5 
1  95  67-123  2 
10  75  57-92  >10  2 
5  73  65-81  2 
1  72  71-72  2 
0.1  65  64-66  2 
10  4  0-11  4.5  3 
5  15  0-31  3 
1  105  80-136  2 
0.1  66  65-66  2 
sion (59% of saline control at 200 ~g/ml). Sialylneolactotetraosylceramide had 
no effect (Table II). Coating of pharyngeal epithelial cells with 200 t~g/ml of neo- 
lactotetraosylceramide  increased  adhesion  (Table  III)  while  sialylneolac- 
totetraosylceramide or giobotetraosylceramide had no effect at the same concen- 
tration. The structures of these compounds are shown in Table I. 
Oligosaccharides.  Of the purified oligosaccharides tested, neolactotetraose and 
lactotetraose  were  the  best  inhibitors,  with  an  EID7~ of  1.5  and  1.0  mg/ml 
(Table III). The "octasaccharide" from human urine had no effect. Lactose was 
inactive. Subsequent studies were concentrated on defining the active site in the 
tetrasaccharide  sequence.  N-acetyl-lactoseamine  and  a-methyl-N-acetyl-lac- 
toseamine were inactive.  Even in  high concentrations/3-methyl and /~-ethyl-N- 
acetyl-lactoseamine  only  partially  reduced  adhesion  (EID75  >  10  mg/ml). 
GIcNAc/31--->3Gal/3-O-Me abolished adhesion at 10 mg/ml with an EID75 of 4.5 
mg/ml. The disaccharide was, thus, three times less active than the tetrasaccha- 
rides  on  a  weight  basis.  The  carbohydrate pneumococcal receptor  was  thus 
proposed to reside in  the trisaccharide unit Gal/31--*4GIcNAc/31---*3GalB- with ANDERSSON  ET  AL. 
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Hemagglutination* 
Glycoconjugate coated* 
Erythrocyte species  Enzyme treated 
Neuramin- 
untreated  Papain  idase  2  3  4 
Uncoated 
Human  blood group O,  -  -  ND  ND 
A, B, or AB 
Human cord blood  -  (+)  -  ND 
Bovine  (+)  +  ++  ND 
Rabbit  -  (+)  +  ++ 
Guinea pig  -  +++  ND  ND 
Sheep  -  -  -  ND 
(+) 
* The hemagglutination was read: (+), some agglutinated and many lysed erythrocytes; +, only few 
agglutinated erythrocytes; ++,  larger aggregates with some free erythrocytes; +++,  most of the 
erythrocytes agglutinated. 
* Rabbit erythrocytes were incubated with glycolipids. The numbers indicate structures in Table I. 
TABLE  VI 
Inhibition of the Adhesion of Various Strains of S. Pneumoniae by Lactotetraose 
Adhesion 
Concentration 
Strain  Capsular type  of saccharide  % of saline control  No. of exp. 
Mean  Range 
mg/ml 
EF1488  15A  10  17  9-25  2 
1  75  65-85  2 
EF2987  23F  10  5  0-9  2 
1  51  48-53  2 
EF3030  19F  10  7  6-7  2 
1  80  75-84  2 
EF3296  4  10  0  --  1 
EF3559  14  10  3  0-3  3 
1  50  40-64  3 
EF7509  25  10  17  12-21  2 
1  160  120-200  2 
EF10175  19F  10  16  6-36  3 
1  63  42-97  3 
GIcNAcI31--*3GaiI3  as the principal binding site. 
To test the generality of binding to GalB1---~3GIcNAcI31--*3Gal/31  ;~Glc as a 
mechanism of pneumococcal adhesion, seven strains with different capsular types 
and high adhesive capacity  were  used.  Adhesion of all  the  strains  tested  was 
inhibited after pretreatment  of the bacteria with lactotetraose (Table  VI).  No 
correlation between inhibition and the capsular type of the pneumococcal strain 
was observed. 
Hemagglutination.  The pneumococcal strains did not agglutinate any of the 
erythrocyte species tested. After papain or neuraminidase treatment guinea pig 
and to a smaller extent bovine erythrocytes became agglutinable (Table V). After 
coating with neolactotetraosylceramide (200 #g/ml) the previously inactive rab- 
bit erythrocytes became agglutinable.  Sialylneolactotetraosylceramide and glo- 566  A  RECEPTOR  FOR  PNEUMOCOCCI  ADHERING  TO PHARYNGEAL  CELLS 
botetraosyiceramide were inactive. 
Discussion 
This study demonstrates specific attachment of pneumococci to glycoconjugate 
receptors where the disaccharide GlcNAc~$1--.3Galfl-  is shown to be the main 
binding site. The high degree of specificity of this binding is shown by the lack 
of activity of GlcNAc$1--~4Gal$-O-Me  (Table  III).  The importance of the  ~- 
configuration of the N-acetylglucoseaminosyl group was  demonstrated by  the 
inhibitory activity of ~-methyl but not a-methyl-N-acetyl-lactoseamine. 
The identification of the receptor was done experimentally in  several  steps 
using inhibition and induction of binding. In analogy with Streptococcus pyogenes, 
the pneumococci bound human plasma fibronectin.  In contrast to S.  pyogenes, 
the  pneumococci  bound  at  the  collagen-binding  region  of fibronectin. 2 The 
partly characterized oligosaccharide sequence at that site contains the "octasac- 
charide" (see 7 in Table I), that did not inhibit adhesion. This does not contain 
the active disaccharide and  did not inhibit adhesion  (Table  III).  Accordingly, 
this part of the fibronectin structure probably is not the pneumococcal binding 
site. The fibronectin-binding may involve other adhesion receptor interactions. 
Receptor  activity  of the  neolactoseries  of glycolipids was  indicated  by  the 
inhibition  of adhesion  obtained  after  pretreatment  of bacteria  with  neolacto- 
tetraosylceramide  and  the  increased  binding  after  coating  of epithelial  cells 
and erythrocytes. Receptor activity of the ~-O linkage per se was unlikely, since 
lactose-~-O-Me  did  not  inhibit  adhesion.  Receptor  activity  of  the  ceramide 
portion  was  ruled  out,  since e.g.  sialylneolactotetraosylceramide  was  inactive. 
The  complete  inhibition  of pneumococcal  adhesion  obtained  with  neolacto- 
tetraose and lactotetraose suggested that the receptor was a common feature of 
these  tetrasaccharides.  Since  lactose,  lactoseamine,  and  the  "octasaccharide" 
(which contains two terminal lactoseamine residues) are all inefficient as inhibi- 
tots,  it  was  thought that  the  central  disaccharide  portion  of lactoneotetraose 
should be the active receptor.  Accordingly, this compound (15 in Table I) was 
synthesized in the form of its B-methyl glycoside. Testing of the inhibitory activity 
supported this assumption. 
The varying ability to agglutinate erythrocytes of different species has been 
useful  for  classifying bacterial  adhesins  (3.5). The  GIcNAcjOl--~3Gal  has  been 
identified as part of the saccharide chains of many glycolipids and glycoproteins 
including long chains containing repeating units of (--~GlcNAc~I--~3GaI~--~) (36, 
37). It has been identified in human (36, 37), ox (38, 39), rabbit (40), and sheep 
(41) erythrocytes, but so far not in guinea pig erythrocytes (42). Thus a correla- 
tion  between  presence  of  receptor-active  oligosaccharide  and  pneumococcal 
hemagglutination was not apparent (Table V) as found between hemagglutina- 
tion by uropathogenic E. coli and the presence of the Galal--~Gal  sequence (2). 
The receptor activity may depend not only on the presence but also on availability 
of the receptor in the cell surface micro-environment (36). 
The identification of the interaction of pneumococci with specific saccharides 
is interesting from many biological and medical points of view. The disaccharide 
GIcNAc~Ol--~3GaI~-  (substituted at various positions) is part of many saccharide 
chains active as blood group ABH,  Lewis, or Ii antigens (37).  Its presence and ANDERSSON  ET  AL.  567 
availability therefore may be subject to variations between individuals, and may 
affect the susceptibility to pneumococcal infection. Compare the relation between 
P  blood  group  phenotype and  urinary  tract  infection  (43).  Our  preliminary 
results indicate that epithelial cells from patients with frequent attacks of otitis 
media have an increased receptivity for adhering pneumococci compared with 
cells from age matched controls (44). The inhibitory effect of receptor oligosac- 
charides in vitro might be used to inhibit bacterial adhesion in vivo. The principal 
usefulness of this approach has been demonstrated in other infections (45, 46). 
Furthermore pneumococcal adhesion was also inhibited by a fraction of human 
milk rich in oligosaccharides and from which antibodies had been removed. The 
natural presence of neolacto- and lactotetraose in human milk and colostrum 
(20) may interfere with pneumococcal colonization in the newborn, and could in 
part explain the suggested positive effect of breast feeding on otitis media (47, 
48). 
Summary 
Glycoconjugates  containing  the  disaccharide  unit  GlcNAc/31--*3Gal/3  were 
suggested as receptors for pneumococci adhering to human pharyngeal epithelial 
cells. The receptor activity was detected both by inhibition of adhesion by an 
excess of free oligosaccharide and by induction or increase of adhesion after 
coating of target cells with glycolipid. Studies with free natural and synthetic 
oligosaccharides identified the  disaccharide GicNAc/31--*3Gal/3  as  one  critical 
binding site.  The specificity of recognition was shown inter alia  by the lack of 
inhibitory activity of GIcNAcI31-->4GalB,  which differs only in the linkage of the 
two sugars. Specific interference with pneumococcal adhesion by administration 
of soluble receptor sugar may improve our understanding of the role of adhesion 
in vivo. 
The pneumococcal isolates were stored by E. Falsen. The glycolipids were isolated in Dr. 
K.-A. Karlsson's group, Department of Medical and Physiological Biochemistry, G6teborg, 
Sweden. The fibronectin was kindly provided by Dr. A. Simpson, Memphis, TN, the R~- 
R4 LPS preparations by Drs. B. and K. Jann, Max-Planck-Institut  fiir Immunbiologie, 
Freiburg, BRD, the milk tetrasaccharides by S. Svensson, Swedish Sugar Company, Arl6v 
and the "octasaccharide" by Dr. A. Lundblad, Department of Clinical Chemistry, Lund, 
Sweden. 
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